🇪🇺 Trizivir in European Union

EMA authorised Trizivir on 27 December 2000

Marketing authorisation

EMA — authorised 27 December 2000

  • Application: EMEA/H/C/000338
  • Marketing authorisation holder: ViiV Healthcare BV
  • Local brand name: Trizivir
  • Indication: Trizivir is indicated for the treatment of human-immunodeficiency-virus (HIV) infection in adults. This fixed combination replaces the three components (abacavir, lamivudine and zidovudine) used separately in similar dosages. It is recommended that treatment is started with abacavir, lamivudine,and zidovudine separately for the first six to eight weeks. The choice of this fixed combination should be based not only on potential adherence criteria, but mainly on expected efficacy and risk related to the three nucleoside analogues. The demonstration of the benefit of Trizivir is mainly based on r
  • Status: approved

Read official source →

Trizivir in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is Trizivir approved in European Union?

Yes. EMA authorised it on 27 December 2000.

Who is the marketing authorisation holder for Trizivir in European Union?

ViiV Healthcare BV holds the EU marketing authorisation.